Medigen presents vaccine research at ASV 2024

Medigen and the University of Louisville (UofL) present collaborative research on V5040 chikungunya vaccine at the Annual meeting of the American Society for Virology in Columbus, OH. Scientists showed that novel vaccine developed by Medigen and UofL is safe, highly immunogenic, and protects C56BL/6J mice from experimental challenge with infectious chikungunya virus. Chikungunya virus [...]

2024-07-13T22:22:27+00:00July 13th, 2024|
Read More

Medigen reports vaccines for Venezuelan Equine Encephalitis and Chikungunya viruses

January 29, 2019. Medigen presented experimental vaccines for two life-threatening emerging viruses at the 2019 ASM Biothreats conference in Washington, DC. Venezuelan Equine Encephalitis (VEE) virus is a mosquito-borne alphavirus that causes periodic disease outbreaks in North, Central, and South Americas including the U.S. Medigen’s VEE vaccine V4020 showed production of virus-neutralizing antibodies and [...]

2019-02-14T05:03:15+00:00January 29th, 2019|
Read More
© Copyright 2018 -    |  Medigen, Inc. All rights reserved. |. 8420 Gas House Pike, Suite S, Frederick, MD 21701 | info@medigen-usa.com
Go to Top